Metastasis, the movement of tumor cells responsible for nearly 90% of cancer deaths, remains a critical and often untargeted stage of the disease. Aiming to bridge this significant gap, Mestastop® Solutions has now raised $500K in Series a funding.
The biotech company is developing unique proprietary platforms - METAssay, METSCAN, and METVivo - designed to overcome the challenges in advancing molecules that specifically address metastasis. While cancer treatment has advanced with targeted therapy and immunotherapy, these often fall short in tackling the complex biology of tumor cell spread, a void Mestastop seeks to fill.
.png&w=3840&q=75)
